Biblio Discovery — Demo Discovery Service

23 hasil untuk "Nicolas Mach"

Menampilkan 1–20 · 2,06 detik · RSS

  1. Artikel Jurnal Teks lengkap

    A Quantitative ELISA Protocol for Detection of Specific Human IgG against the SARS-CoV-2 Spike Protein

    Rémi Vernet; Emily Charrier; Julien Grogg dkk.

    Vaccines, Vol. 9 No. 7 · 2021 · Inggris · DOAJ Scopus

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic with at least 3.8 million deaths to date. For that reason, finding an efficient vaccine for this virus quickly became a global priority. The majority of vaccines now marketed are based on the SARS-CoV-2…

  2. Artikel Jurnal Teks lengkap

    A Functional GM-CSF Receptor on Dendritic Cells Is Required for Efficient Protective Anti-Tumor Immunity

    Emily Charrier; Rémi Vernet; Frank Schwenter dkk.

    Immuno, Vol. 1 No. 3 · 2021 · Inggris · DOAJ Scopus

    Dendritic cells (DC) play a major role during the priming phase of anti-tumor immunization, as they are required for an efficient tumor-associated antigens presentation. At least one dendritic cell-based therapy has already been successfully approved by regulators for clinical application in…

  3. Artikel Jurnal Teks lengkap

    Local Sustained GM-CSF Delivery by Genetically Engineered Encapsulated Cells Enhanced Both Cellular and Humoral SARS-CoV-2 Spike-Specific Immune Response in an Experimental Murine Spike DNA Vaccination Model

    Rémi Vernet; Emily Charrier; Erika Cosset dkk.

    Vaccines, Vol. 9 No. 5 · 2021 · Inggris · DOAJ Scopus

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic with recurrences. Therefore, finding a vaccine for this virus became a priority for the scientific community. The SARS-CoV-2 spike protein has been described as the keystone for viral entry into cells and…

  4. Artikel Jurnal Teks lengkap

    Intestinal Colonization of IL-2 Deficient Mice with Non-Colitogenic B. vulgatus Prevents DC Maturation and T-Cell Polarization

    Martina Müller; Kerstin Fink; Julia Geisel dkk.

    PLoS ONE, Vol. 3 No. 6 · 2008 · Inggris · PLOS Scopus

    Background: IL-2 deficient (IL-2−/−) mice mono-colonized with E. coli mpk develop colitis whereas IL-2−/−-mice mono-colonized with B. vulgatus mpk do not and are even protected from E. coli mpk induced colitis. Methodology/Principal Findings: We investigated if mono-colonization with E. coli mpk or…

    Juga tersedia di: DOAJ

  5. Artikel Jurnal

    Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice

    Richard Cathomas; Julian Schardt; Miklos Pless dkk.

    Swiss Medical Weekly, Vol. 150 No. 1920 · 2020 · Inggris · DOAJ Scopus

    AIMS OF THE STUDY Atezolizumab is an approved therapy for urothelial carcinoma based on results from the IMvigor 210 and IMvigor211 phase II and III trials. The global SAUL study evaluated atezolizumab in a broader patient population more representative of real-world populations. Among…

  6. Artikel Jurnal

    Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B‐cell lymphoma: Insights from real‐life clinical practice

    Jasmine Mohamad; Antonin Bouroumeau; Thomas A. McKee dkk.

    Cancer Reports, Vol. 7 No. 10 · 2024 · Inggris · DOAJ Scopus

    Abstract Background Tumor lysis syndrome (TLS) is a potentially life‐threatening condition resulting from the rapid destruction of malignant cells, leading to electrolyte imbalances and severe complications, such as acute kidney injury, arrhythmias, and seizures. TLS can be managed through…

  7. Artikel Jurnal

    First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies

    Denis Migliorini; Nicolas Mach; Diego Aguiar dkk.

    OncoImmunology, Vol. 6 No. 8 · 2017 · Inggris · DOAJ Scopus

    Chordoma is a rare tumor of notochordal origin, currently principally treated by surgery and/or irradiation. Here, we describe the clinical outcome of 3 consecutive patients with metastatic and locally advanced chordoma, treated with different immunotherapeutic approaches. All patients presented…

  8. Artikel Jurnal

    Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity

    Patrick Petignat; Manuela Undurraga; Christian Toso dkk.

    BMJ Open, Vol. 13 No. 1 · 2023 · Inggris · DOAJ Scopus

    Introduction Intraperitoneal dissemination is a major problem resulting in very poor prognosis and a rapid marked deterioration in the quality of life of patients. Pressurised intraperitoneal aerosol chemotherapy (PIPAC) is an emergent laparoscopic procedure aiming to maximise local efficacy and to…

  9. Artikel Jurnal

    Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins

    Julien Grogg; Remi Vernet; Emily Charrier dkk.

    iScience, Vol. 26 No. 8 · 2023 · Inggris · DOAJ Scopus

    Summary: Encapsulated cell therapy holds a great potential to deliver sustained levels of highly potent therapeutic proteins to patients and improve chronic disease management. A versatile encapsulation device that is biocompatible, scalable, and easy to administer, retrieve, or replace has yet to…

  10. Artikel Jurnal

    Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology

    Aurelien Lathuiliere; Remi Vernet; Emily Charrier dkk.

    Molecular Therapy: Methods & Clinical Development, Vol. 26 · 2022 · Inggris · DOAJ

    Despite many promising results obtained in previous preclinical studies, the clinical development of encapsulated cell technology (ECT) for the delivery of therapeutic proteins from macrocapsules is still limited, mainly due to the lack of an allogeneic cell line compatible with therapeutic…

  11. Artikel Jurnal Teks lengkap

    Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

    Giuseppe Curigliano; Hans A. J. Gelderblom; Nicolas Mach dkk.

    Clinical Cancer Research · 2021 · Inggris · OpenAlex Scopus

    Abstract Purpose: Sabatolimab (MBG453) and spartalizumab are mAbs that bind T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and programmed death-1 (PD-1), respectively. This phase I/II study evaluated the safety and efficacy of sabatolimab, with or without spartalizumab, in patients with…

  12. Artikel Jurnal

    Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study

    Toshihiko Doi; David Tai; Dong-Wan Kim dkk.

    BMJ Open, Vol. 14 No. 8 · 2024 · Inggris · DOAJ Scopus

    Objective This study evaluates the safety/efficacy of sabatolimab plus spartalizumab in patients with melanoma or non-small cell lung cancer (NSCLC).Design, setting and participants This is a phase 1–1b/2, open-label, multinational, multicentre study of patients with advanced/metastatic melanoma or…

  13. Artikel Jurnal Teks lengkap

    SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

    Sacha I. Rothschild; Alfred Zippelius; Eric Innocents Eboulet dkk.

    Journal of Clinical Oncology · 2021 · Inggris · OpenAlex Scopus

    PURPOSE: For patients with resectable stage IIIA(N2) non-small-cell lung cancer, neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% in the SAKK 16/00 trial and is an accepted standard of care. We investigated the…

  14. Artikel Jurnal Teks lengkap

    SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients

    Natacha Bordry; Anne-Claire Mamez; Chiara Fedeli dkk.

    Vaccines, Vol. 11 No. 8 · 2023 · Inggris · DOAJ Scopus

    Immunocompromised patients (ICPs) have a higher risk of developing severe forms of COVID-19 and experience a higher burden of complications and mortality than the general population. However, recent studies have suggested that the antibody response to SARS-CoV-2 mRNA vaccines could be highly…

  15. Artikel Jurnal

    Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer

    Natacha Bordry; Alfredo Addeo; Cyril Jaksic dkk.

    iScience, Vol. 25 No. 1 · 2022 · Inggris · DOAJ Scopus

    Summary: Little is known on the long-lasting humoral response and the T cell activation induced by SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-CoV-2 mRNA vaccines through measuring the seroconversion rate at pre-specified time points and the effect…

  16. Artikel Jurnal

    Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial

    Eugenio Fernandez; Rémi Vernet; Muriel Urwyler dkk.

    Experimental Hematology & Oncology, Vol. 14 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Background Over the past two decades, most cancer vaccines have failed to be developed clinically. The lack of efficient priming with specific tumor antigens and/or weak adjuvants may explain this poor success rate. MVX-ONCO-1, a personalized cell-based vaccine, combines inactivated…

  17. Artikel Jurnal

    Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Research in context

    Urban Novak; Martin Fehr; Sämi Schär dkk.

    EClinicalMedicine, Vol. 64 · 2023 · Inggris · DOAJ Scopus

    Summary: Background: The Bruton's tyrosine kinase inhibitor ibrutinib and the proteasome inhibitor bortezomib have single-agent activity, non-overlapping toxicities, and regulatory approval in mantle cell lymphoma (MCL). In vitro, their combination provides synergistic cytotoxicity. In this…